Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 31758-31759 [2018-14641]
Download as PDF
<![CDATA[
31758
Federal Register / Vol. 83, No. 131 / Monday, July 9, 2018 / Notices
SUMMARY OF ANNUAL BURDEN
Type of
burden
Assessment Rate Adjustment Guidelines
for Large and Highly
Complex Institutions.
Total Hourly Burden.
Reporting .......
Required to
Obtain or
Retain Benefits.
........................
........................
General Description of Collection:
These guidelines established a process
through which large and highly
complex depository institutions could
request a deposit insurance assessment
rate adjustment from the FDIC.
There is no change in the method or
substance of the collection. The overall
reduction in burden hours is the result
of economic fluctuation. In particular,
the number of respondents has
decreased while the hours per response
and frequency of responses have
remained the same.
Request for Comment
Comments are invited on: (a) Whether
the collection of information is
Estimated
frequency
per
respondent
Estimated
number of
respondents
Obligation to
respond
Estimated
time per
response
Frequency of
response
1
1
80.00
On Occasion ..
80
........................
........................
........................
........................
80
necessary for the proper performance of
the FDIC’s functions, including whether
the information has practical utility; (b)
the accuracy of the estimates of the
burden of the information collection,
including the validity of the
methodology and assumptions used; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. All comments will become
a matter of public record.
Dated at Washington, DC, on July 2, 2018.
Federal Deposit Insurance Corporation.
Robert E. Feldman,
Executive Secretary.
[FR Doc. 2018–14540 Filed 7–6–18; 8:45 am]
BILLING CODE 6714–01–P
FEDERAL DEPOSIT INSURANCE
CORPORATION
Notice to All Interested Parties of
Intent To Terminate Receivership
Notice is hereby given that the Federal
Deposit Insurance Corporation (FDIC or
Receiver) as Receiver for the institution
listed below intends to terminate its
receivership for said institution.
Receivership name
City
State
10165 ...................................
sradovich on DSK3GMQ082PROD with NOTICES
Fund
Peoples First Community Bank ........................................
Panama ...............................
FL .....
The liquidation of the assets for the
receivership has been completed. To the
extent permitted by available funds and
in accordance with law, the Receiver
will be making a final dividend
payment to proven creditors.
Based upon the foregoing, the
Receiver has determined that the
continued existence of the receivership
will serve no useful purpose.
Consequently, notice is given that the
receivership shall be terminated, to be
effective no sooner than thirty days after
the date of this notice. If any person
wishes to comment concerning the
termination of the receivership, such
comment must be made in writing,
identify the receivership to which the
comment pertains, and sent within
thirty days of the date of this notice to:
Federal Deposit Insurance Corporation,
Division of Resolutions and
Receiverships, Attention: Receivership
Oversight Department 34.6, 1601 Bryan
Street, Dallas, TX 75201.
No comments concerning the
termination of this receivership will be
VerDate Sep<11>2014
18:00 Jul 06, 2018
Jkt 244001
considered which are not sent within
this time frame.
Dated at Washington, DC, on July 3, 2018.
Federal Deposit Insurance Corporation.
Robert E. Feldman,
Executive Secretary.
[FR Doc. 2018–14592 Filed 7–6–18; 8:45 am]
BILLING CODE 6714–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
PO 00000
Total
annual
estimated
burden
hours
Frm 00044
Fmt 4703
Sfmt 4703
Date of
appointment
of receiver
12/18/2009
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than July 30, 2018.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
E:\FR\FM\09JYN1.SGM
09JYN1
Federal Register / Vol. 83, No. 131 / Monday, July 9, 2018 / Notices
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. American Heartland Bancshares,
Inc., Sugar Grove, Illinois; to acquire
100 percent of the voting shares of
Community Holdings Corporation and
thereby indirectly acquire First Secure
Bank and Trust Company, both of Palos
Hills, Illinois.
Board of Governors of the Federal Reserve
System, July 3, 2018.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2018–14641 Filed 7–6–18; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–1895]
Indications and Usage Section of
Labeling for Human Prescription Drug
and Biological Products—Content and
Format; Draft Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled
‘‘Indications and Usage Section of
Labeling for Human Prescription Drug
and Biological Products—Content and
Format.’’ This guidance is intended to
assist applicants in writing the
Indications and Usage section of
labeling. The recommendations in this
draft guidance are intended to help
ensure that the labeling is clear, concise,
useful, and informative and, to the
extent possible, consistent in content
and format within and across drug and
therapeutic classes.
DATES: Submit either electronic or
written comments on the draft guidance
by September 7, 2018 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
sradovich on DSK3GMQ082PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
VerDate Sep<11>2014
18:00 Jul 06, 2018
Jkt 244001
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–D–1895 for ‘‘Indications and
Usage Section of Labeling for Human
Prescription Drug and Biological
Products—Content and Format; Draft
Guidance for Industry; Availability.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
31759
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002, or the Office of Communication,
Outreach and Development, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993–0002.
Send one self-addressed adhesive label
to assist the office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT: Iris
Masucci, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 51, Silver Spring, MD
20993–0002, 301–796–2500; or Stephen
Ripley, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993–0002, 240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
E:\FR\FM\09JYN1.SGM
09JYN1
]]>Agencies
[Federal Register Volume 83, Number 131 (Monday, July 9, 2018)]
[Notices]
[Pages 31758-31759]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-14641]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The applications listed below, as well as other related filings
required by the Board, are available for immediate inspection at the
Federal Reserve Bank indicated. The applications will also be available
for inspection at the offices of the Board of Governors. Interested
persons may express their views in writing on the standards enumerated
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the
acquisition of a nonbanking company, the review also includes whether
the acquisition of the nonbanking company complies with the standards
in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted,
nonbanking activities will be conducted throughout the United States.
Unless otherwise noted, comments regarding each of these
applications must be received at the Reserve Bank indicated or the
offices of the Board of Governors not later than July 30, 2018.
A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant
Vice
[[Page 31759]]
President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:
1. American Heartland Bancshares, Inc., Sugar Grove, Illinois; to
acquire 100 percent of the voting shares of Community Holdings
Corporation and thereby indirectly acquire First Secure Bank and Trust
Company, both of Palos Hills, Illinois.
Board of Governors of the Federal Reserve System, July 3, 2018.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2018-14641 Filed 7-6-18; 8:45 am]
BILLING CODE P
